On November 6, 2024, Michael Henderson, Chief Executive Officer of Apogee Therapeutics Inc (APGE, Financial), executed a sale of 15,000 shares of the company. The transaction was filed on the same day with the SEC. Following this transaction, the insider now owns 1,339,487 shares of Apogee Therapeutics Inc.
Apogee Therapeutics Inc is engaged in the development and commercialization of various therapeutic treatments. The company focuses on innovative solutions to address unmet medical needs in the healthcare sector.
According to the market cap data, Apogee Therapeutics Inc is valued at approximately $3.46 billion. The stock was priced at $59.22 on the day of the transaction. This valuation reflects various financial metrics such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
Over the past year, Michael Henderson has sold a total of 150,000 shares and has not made any purchases. The insider transaction history for Apogee Therapeutics Inc shows no insider buys in the past year, with a total of 11 insider sells recorded during the same period.
For more detailed valuation, investors might consider looking at the GF Value of the stock to assess its potential fair value and future performance.
This sale by the insider could be part of personal financial management or portfolio adjustments. Investors often monitor insider transactions as they can provide insights into how the company's top executives view the stock's value and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
